These cf-tDNA-unique variants are targetable primarily with small molecules that inhibit PI3K/AKT/mTOR, RTK/RAS, or P53 signaling pathways (Supplementary Figure 1), all of which have been approved in other cancers and are being tested clinically in gliomas. Here, TP53 is linked to central nervous system cancer.